Latest News & Features
%20(1).jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/85d570c0-120c-11ef-bfe1-7f53b05b4353-Morton_Jeff_1100x1100%20(1)%20(1).webp)
Careers
Growing demand from life sciences and healthcare clients prompts an expansion in California, bringing the firm closer to biotechnology companies, research institutions and key courts for its Southern California litigators. 14 October 2026
.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/4ae9ded0-c7f2-11f1-b7d1-f52eb995587f-Untitled%20design%20(15).webp)
Pharma
Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition. 14 October 2026
Pharma
Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise. 13 October 2026
Regulation & Industry
Potential reforms to post-employment restrictions and contractual notice periods could make it harder for brand owners to protect trade secrets and manage staff departures, prompting questions about how businesses can safeguard their interests. 13 October 2026
MedTech
The two major medical device makers are clashing over Atraverse’s Hotwire system, with Boston Scientific claiming the product infringes its patented radiofrequency transseptal-access technology, used in heart surgery. 12 October 2026
Careers
Ouro Preto Paranhos has brought in a licensed pharmacist with more than 26 years of intellectual property experience to lead the patent practice at the Rio de Janeiro firm. 12 October 2026
Regulation & Industry
As the AIPPI World Congress returned to Germany for the first time in nearly half a century, it heard calls for greater international cooperation and legal harmonisation, highlighting why diversity matters for the future of IP and brand owners. 9 October 2026
Pharma
Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen. 8 October 2026
Pharma
Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations. 8 October 2026
Careers
The firm has snapped up IP partners from Sheridan Ross as it ramps up its presence in Denver and targets growing demand from life sciences and technology clients. 8 October 2026